News | May 27, 2014

Terumo Collaborates With Kaneka For Therapeutic Apheresis System

Multi-year collaboration agreement for the combined use of therapeutic apheresis and columns for LDL reduction

May 27, 2014 — Terumo BCT has entered into a business relationship with Kaneka to gain market authorization in the United States for the use of the Terumo BCT Spectra Optia Apheresis System with the Kaneka Liposorber LA-40S LDL Adsorption Column for cardiologists treating patients with high cholesterol.

Through this new agreement, Terumo BCT and Kaneka will collaborate to seek the required approvals for the use of the Spectra Optia system and the Liposorber column to treat patients with coronary heart disease and severe hyper cholesterolemia, thereby expanding clinical treatment options for clinicians in the United States.

Key Facts on the Regulatory Pathway:

  • Kaneka will seek to obtain Investigational Device Exemption (IDE) for the Liposorber column
  • Terumo BCT will support the IDE application by providing data references for the Spectra Optia device, the Spectra Optia SPD Holder and the Spectra Optia SPD-C Connection Set
  • Terumo BCT and Kaneka will collaborate on a U.S. clinical trial that is planned to evaluate the Liposorber column when used with the Spectra Optia device
  • When the clinical trials are complete, Kaneka will submit a pre-market approval (PMA) application for the Liposorber column and Terumo BCT will submit a 510(k) for Spectra Optia Therapeutic Plasma Exchange (TPE) with a Secondary Plasma Device procedure (TPE-SPD procedure)
  • The devices are expected to be used together in the treatment of patients with severe hypercholesterolemia once the necessary regulatory approvals are obtained           

Key Facts on the Patient Condition:

  • High LDL cholesterol (LDL-C) levels in the blood significantly increase the risk of coronary heart disease and heart attacks
  • LDL-apheresis, when performed with an LDL adsorption column that binds to and removes LDL-C from a patient’s plasma, is a treatment option for high-risk patient populations — such as those with familial hypercholesterolemia (FH) for whom diet, exercise and drug therapies such as statins have either been ineffective, or not tolerated
  • The number of FH patients in the United States is more than 600,000; it is estimated that 12,000 of these patients are unresponsive to standard therapies [1]
  • Despite the prevalence of FH and the availability of effective treatment options, FH is both under diagnosed and undertreated [1]
  • When LDL-apheresis is prescribed, it is usually performed once every two weeks, or once per week in severe cases

For more information: www.terumobct.com, www.kaneka.co.jp/kaneka-e/

References:

1. Goldberg, A “Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients.” The Journal of Clinical Lipidology 2011; 5: 133–140.

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init